Metraipolis › archive › dc_baebe49f5e87

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for… — Europe PMC PMID:40783751

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40783751
DOI
10.1186/s12885-[numero omesso]-0
License (as archived)
solo-consultazione
Archived
2026-11-10T18:39:43.967Z
SHA-256 of the archived text
db255bb314a3b5d305c1d29f5223e93e844b698e9bc6d3bbc5ad7888024b0b42
Stable URL of this page
https://metraipolis.com/documento/dc_baebe49f5e87

How to cite

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for… — Europe PMC PMID:40783751 — Europe PMC (en), https://europepmc.org/article/MED/40783751 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_baebe49f5e87 (Metraipolis archive dc_baebe49f5e87, sha256 db255bb314a3b5d305c1d29f5223e93e844b698e9bc6d3bbc5ad7888024b0b42)
BibTeX
@misc{dcbaebe49f5e87,
  title = {Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for… — Europe PMC PMID:40783751},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40783751},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_baebe49f5e87; sha256 db255bb314a3b5d305c1d29f5223e93e844b698e9bc6d3bbc5ad7888024b0b42},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40783751. Agents can read the archived copy with the MCP tool read_document.